UBS Maintains Buy on Bausch & Lomb, Raises Price Target to $23

Nicox Announces Extension of Cash Runway

Nicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.

HC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Maintains $21 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $21 price target.

Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential

Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.

Bausch + Lomb Says Dual-Action Dry Eye Drop Missed Phase 2 Primary Endpoint At Day 29, Met Secondary Endpoint At Day 15; Advancing To Phase 3 With Day 15 Primary Endpoint